News Features ‘Buzz and Discussion’ Driving Return to In-Person Cardiology Meetings Michael O'Riordan September 17, 2025
News Features What’s in a Name: Is It Time to Choose Between TAVI and TAVR? Yael L. Maxwell March 27, 2025
News Features Once Burned, Twice Shy, Cardiologists Ditch X for Bluesky Yael L. Maxwell November 29, 2024
News Features After DanGer Shock’s Win in AMICS for Impella: What’s Next? Caitlin E. Cox May 02, 2024
News Features A Sham-Controlled Trial of AF Ablation Is Feasible, but Is It Needed? Todd Neale January 25, 2024
News Features Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR Todd Neale October 17, 2022
News Features A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts Shelley Wood July 07, 2022
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021
News Features Low Numbers and ‘Anecdata’: Shoddy Research Rode COVID-19’s First Wave Michael O'Riordan January 11, 2021
News Features From Heroes to Humans: How Doctors Found Their Voices in 2020 Caitlin E. Cox December 21, 2020
News Features Walloped by COVID-19, US Cardiology Practices Brace for Slow Recovery Todd Neale July 29, 2020
News Features COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions Shelley Wood July 20, 2020
News Features Hydroxychloroquine: No Help, Clear Harm in COVID-19 RCT and Cohort Studies Shelley Wood May 20, 2020
News Features Dire, Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance Shelley Wood April 29, 2020
News Features Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too Michael O'Riordan December 09, 2019
News Features ESC Heart Failure 2019 At the ESC Heart Failure Congress, Some COAPT Converts—and Some Pushback Shelley Wood May 30, 2019
News Features The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine Shelley Wood October 22, 2018